title: Effect of antiatherogenic L-aspartate and L-glutamate on serum lipoproteins cholesterol and apolipoproteins A-1 and B in rabbits fed with high cholesterol diet.
abstract: OBJECTIVE
  It has been shown that aspartate and glutamate inhibit mononuclear cell adhesion to the endothelium and formation of foam cells in the intima of thoracic aorta in cholesterol-fed rabbits. The purpose of the present study was to investigate whether a high cholesterol diet supplemented with aspartate and glutamate may alter lipoproteins cholesterol and apolipoproteins A-1 and B levels in rabbits.
  
  
  RESULTS
  Serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein A-1 (apoA-1), apolipoprotein B (apoB), atherogenic index (AI) and apoA-1/apoB ratio were determined in 17 male New Zealand white rabbits fed a cholesterol plus corn oil diet (control group) or the same diet supplemented with aspartate and glutamate (Asp+Glu group) for 4 weeks. Both diets were found to increase TC, LDL-C, apoB and AI, while apoA-1/apoB ratio was decreased compared to baseline values. TG did not seem to be affected in the 4 weeks time in both groups. There was a significant increase of HDL-C in Asp+Glu group and a marked decrease of apoA-1 in control group during the study.
  
  
  CONCLUSIONS
  Oral administration of aspartate and glutamate has been shown to inhibit fatty streak initiation in cholesterol-fed rabbits. The two amino acids did not have any effect on serum TC, LDL-C, TG and apoB concentrations. However, they increased HDL-C and maintained apoA-1 levels. Their antiatherogenic effect probably may be explained by different mechanisms than these related to the atherogenic lipids lowering, and it is possible to involve HDL-C and apoA-1.
authors.affiliation: The Laboratory of Nutrition and Clinical Dietetics, Department of Nutrition and Dietetics, Harokopio University, 70 El. Venizelou Av., 176 71 Athens, Greece. ayanni@hua.gr
authors.forename: Amalia E
authors.initials: AE
authors.lastname: Yanni
authors.forename: Despoina N
authors.initials: DN
authors.lastname: Perrea
authors.forename: Hippocrates A
authors.initials: HA
authors.lastname: Yatzidis
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood / Q000187:drug effects; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood / Q000187:drug effects; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood*; D002791:Cholesterol, Dietary / Q000008:administration & dosage* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D018698:Glutamic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D011817:Rabbits; D011897:Random Allocation; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D001224:Aspartic Acid; D018698:Glutamic Acid; D002784:Cholesterol